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Abstract 
Although drug-eluting stents (DES) have become the mainstay of percutaneous coronary 
intervention, late and very late stent thrombosis remains a concern. Drug-coated balloons 
(DCB) have the advantage of preserving the anti-restenotic benefits of DES while minimizing 
potential long-term safety concerns. Currently the two methods to ensure successful DCB 
treatment of a stenotic lesion are angiography or physiology-guided DCB application. This 
review will evaluate these two methods based on previous evidence and make suggestions on 
how to perform DCB treatment more efficiently and safely. 
Key words: drug-coated balloon, coronary artery disease, physiology, fractional flow 
reserve, diameter stenosis, de novo lesion  
 
 
Introduction 
The successful restoration of coronary flow is the goal of percutaneous coronary 
intervention (PCI) for obstructive coronary artery disease. Due to the limitations of accurately 
measuring blood flow in clinical practice, anatomical assessment using diameter stenosis 
(DS) or minimal lumen diameter by coronary angiography has been used to guide the 
procedure. However, coronary angiography alone is inherently limited by its inability to 
provide information pertaining to the functional significance of stenoses. Fractional flow 
reserve (FFR) was developed as a technique to enable physiological assessment of coronary 
lesions. FFR expresses the maximum achievable blood flow to the myocardium supplied by a 
stenotic artery as a fraction of normal maximum flow. As such, it provides an objective 
measure of the hemodynamic significance of an epicardial stenosis and FFR-guided PCI is 
associated with a better prognosis than angiography-guided PCI [1].  
Drug-coated balloons (DCB) provide local drug delivery after successful balloon 
angioplasty (BA) to inhibit restenosis, however concerns over acute vessel closure, have 
hampered their use for de novo lesions. During the BA era, Bech et al. [2] demonstrated that 
patients with a residual DS of  35% and an FFR value after BA of ≥ 0.90 had excellent 
clinical outcomes to 2-years. Further, in a previous study, it was demonstrated that DCB 
treatment after successful BA with a resultant FFR value ≥ 0.75 was safe and effective, 
without the additional risk of acute vessel closure [3].  
One of the advantages using a DCB over drug-eluting stent (DES) is the short duration 
of dual antiplatelet therapy (DAPT) especially in patients with high risk of bleeding, and in 
those with contraindications to long term DAPT, since they require only 1 month of DAPT. 
Although the latest data from the Onyx ONE and EVOVE Short DAPT studies demonstrated 
that 1 to 3 months of DAPT is noninferior to the standard 12-month DAPT in terms of the 
risk of stent thrombosis [4, 5], neoatherosclerosis with DES is inevitable over time, and this is 
known to progress faster than de novo lesions, resulting in stent failure manifesting as 
restenosis and thrombosis [6]. Nevertheless, unlike the BA era, there are now two available 
options — DCB and DES — for the local delivery of antiproliferative drugs allowing patients 
to receive different treatment options. There have been many efforts to examine the pros and 
cons of DCB compared to DES, and an indication standard for DCB treatment is expected in 
the near future. This review discusses a safe and effective method for the use of DCBs in the 
treatment of obstructive coronary artery disease. 
 
Optimal lesion preparation for DCB application 
The use of DCBs has been proven to be very effective for in-stent restenosis (ISR) and is 
recommended by European, German, and Asia-Pacific consensus groups [7–9]. Although 
DCB treatment is a reasonable option for ISR, recurrent target lesion failure (TLF) still 
occurs in some patients after treatment. Optimal lesion preparation for ISR plays an important 
role in reducing adverse clinical outcomes after DCB treatment. The RIBS IV study 
investigated the treatment of patients with DES-ISR, and showed that re-stenting with a DES 
reduced the 1-year composite outcome of cardiac death, myocardial infarction (MI), and 
target vessel revascularization (TVR) compared with using a DCB (10% vs. 18%; hazard 
ratio [HR]: 0.58; 95% confidence interval [CI]: 0.35–0.98; p = 0.04). However, this benefit 
was driven in part due to sub-optimal lesion preparation and inadequate flow after balloon 
angioplasty in the DCB arm [10]. Another recent study showed that modifiable independent 
predictors of recurrent TLF were residual DS after lesion preparation, DCB-to-stent ratio, and 
DCB inflation time [11]. In their study, TLF occurred in 20.3% and the best cutoff values 
were 20%, 0.91, and 60 s for residual DS, DCB-to-stent ratio, and DCB inflation time, 
respectively. TLF rates were significantly higher in groups with residual DS ≥ 20% (34.7% 
vs. 12.5%; HR: 2.15; 95% CI: 1.86–2.48; p < 0.001), DCB-to-stent ratio ≤ 0.91 (46.4% vs. 
21.9%; HR: 2.02; 95% CI: 1.75–2.34; p < 0.001), and inflation time ≤ 60 s (26.2% vs. 14.0%; 
HR: 1.82; 95% CI: 1.36–2.45; p < 0.001). When classifying ISR lesions by combination of 
three procedure-related factors, TLF occurred in 8.3% in the fully optimized procedure group 
and 66.7% in the non-optimized group (p < 0.001), demonstrating clearly that fully optimized 
DCB treatment with ideal lesion preparation, sufficient dilatation, and prolonged inflation 
could reduce TLF. Appropriate lesion preparation can create an environment that allows 
homogeneous drug delivery to the lesion efficiently and thus, has a significant impact on the 
efficacy and safety of DCB treatment.  
There is no evidence of criteria for optimal lesion preparation for de novo coronary 
artery lesions. In ISR as well as in de novo lesions, conventional lesion preparation is 
performed using a non- or semi-compliant balloon. In complex lesions, however, the use of 
high-pressure non-compliant balloons or scoring/cutting balloons should be considered to 
provide better lesion preparation. The shortcomings of conventional balloon angioplasty 
include balloon slippage and edge dissections, post procedure, and these problems could be 
reduced with the use of a scoring balloon, which may also allow enhanced local drug uptake. 
In an early intravascular ultrasound evaluation study comparing cutting balloons with 
conventional balloons for the treatment of ISR, the luminal area acute gain was larger in the 
cutting balloon group due to more effective tissue extrusion, while late loss was smaller [14]. 
Cutting or scoring the neointimal plaque lessens the elastic and fibrotic continuity of the 
internal fibrous layer and makes the tissue more amenable to being pushed outward through 
the stent struts. In the ISAR-DESIRE 4 study, neointimal modification with scoring balloon 
before DCB was compared with standard DCB therapy in patients with ISR [15]. Pre-
dilatation with a scoring balloon resulted in a significantly lower rate of in-segment 
percentage DS (35.0 ± 16.8% vs. 40.4 ± 21.4%, p = 0.047) and binary angiographic 
restenosis rate (18.5% vs. 32.0%, p = 0.026) at 6–8 month follow-up. The results 
demonstrated that the use of a scoring balloon improves the complete expansion of a re-
stenosed stent, neointimal modification, and homogeneous drug delivery and hence, increases 
the anti-restenotic efficacy of DCB treatment. 
ST-segment elevation myocardial infarction (STEMI) is the most representative disease 
of atherothrombotic lesions. In STEMI patients, stent implantation reduces target lesion 
revascularization (TLR), however, it tends to increase the long-term risk of stent-related 
events such as stent thrombosis and ISR [16–18]. In the majority of STEMI patients, rapid 
restoration of coronary flow is the main purpose of treatment, and this can be achieved by a 
combined approach of pharmacologic and interventional treatments without stenting. 
Thrombus aspiration is an adjunctive non-pharmacological strategy during primary PCI 
designed to improve epicardial and myocardial reperfusion. However, recent studies failed to 
show the clinical benefit of aspiration thrombectomy in STEMI patients due to insufficient 
removal of thrombus at the culprit lesion [19–21].  
Stenting has been shown to reduce the need for target vessel revascularization in acute 
MI, however, this was not associated with a significant reduction in mortality or reinfarction 
compared with BA [22]. To avoid the long-term risk of stent-related events in STEMI 
patients, a DCB strategy in primary PCI could be a safe and feasible alternative strategy to 
DES treatment if coronary flow is restored and no significant residual stenosis persists after 
balloon dilatation or thrombo-suction. Before using a DCB, successful thrombus aspiration is 
important and has beneficial effects considering that adequate lesion preparation helps 
facilitate homogeneous drug delivery. In the REVELATION study, a DCB strategy was 
noninferior to DES in STEMI patients in terms of FFR assessed at 9 months (0.92 ± 0.05 vs. 
0.91 ± 0.06, p = 0.27), and during follow-up, only 2 patients received a non-urgent TLR (1 in 
each group) [23]. One option in STEMI patients where coronary flow is restored and no 
significant residual stenosis is observed after balloon pre-dilatation, is medical treatment with 
an anticoagulant and antiplatelet agent without any further immediate intervention, followed 
by a repeat coronary angiogram after 1–2 weeks to decide whether to use a DCB or DES. The 
high risk of restenosis and stent thrombosis in patients with a chronic total occlusion (CTO) 
is still a major problem. In the PEPCAD-CTO study, the use of DCB plus BMS was 
associated with similar clinical results and a non-significantly higher in-stent late loss 
compared with DES [24]. The DCB only approach studies for CTO cases are scarce but 
recent registry data has suggested it was a feasible and well-tolerated treatment method if the 
pre-dilatation result is good [25]. In their feasibility and safety study, the incidence of 
angiographic restenosis was 11.8% at mean 8-month follow-up, which were similar or lower 
than prior CTO studies using either DES or BMS. Furthermore, late lumen gain was found in 
67.6% of patients and was caused by an increase in vessel size rather than plaque regression. 
When a DES is used after successful recanalization of a CTO, the stent may be 
undersized because the lesion was occluded, and the vessel did not grow soon after 
reperfusion. CTO lesions have negative remodeled distal vessels because they have not had 
any flow for a long time. After BA, antegrade flow increases and vessels become larger, 
however this may take from several weeks to months. Therefore, immediately after balloon 
angioplasty of a CTO, it is easy to under-estimate the true vessel size, increasing the risk of 
stent under-sizing and subsequent risks of restenosis, late stent mal-apposition and stent 
thrombosis. Moreover, the metallic cage can inhibit positive remodeling leaving a small 
luminal size after vessel recovery. However, after treatment with a DCB, it is possible that 
vessels will return to their original size over time, which is one of the greatest advantages of 
DCB treatment in CTO lesions. Furthermore, in cases of DCB only treatment, the presence of 
heavy calcification could support the vessel as a DES does, and could give the vessel a 
chance to grow and heal. However, larger, randomized controlled trials are necessary to 
further evaluate the DCB-only approach for CTO lesions. 
 
Provisional strategy guided by physiology 
According to the German Consensus Group, lesion characteristics determined by 
angiography after BA can identify acceptable lesion preparation by assessing for the absence 
of a flow-limiting dissection and a non-significant residual DS ≤ 30% [8]. Angiographically 
significant parameters after BA are residual DS > 30% or dissection type C or more. Recently 
it was demonstrated that DCB treatment could be performed safely and effectively after 
successful BA (Thrombolysis In Myocardial Infarction [TIMI] flow grade 3 after BA) with 
an FFR value ≥ 0.75, without any increased risk of acute vessel closure and a lower rate of 
restenosis. Of note, a high frequency of non-concordance was found between angiographic 
and functional characteristics when using an FFR after BA cutoff of 0.75 to define 
functionally significant lesions [1]. The results showed a mismatch of 68.7% (residual DS > 
30% and FFR after BA ≥ 0.75) with a reverse mismatch (residual DS ≤ 30% and FFR after 
BA < 0.75) in 7.1% (Fig. 1A). If these mismatch lesions were treated solely using 
angiography, as recommended by the German consensus group, all of them should be treated 
with stent implantation, since the residual DS was above 30%, even though the post-balloon 
FFR was > 0.75. Previous mid- and long-term follow-up studies in patients with an FFR after 
BA ≥ 0.75 showed comparable clinical outcomes between DCB and stent treatments [1, 3, 
12]. Therefore, FFR-guided DCB treatment could safely reduce the number of unnecessary 
stent implantations in this mismatch population. In the reverse mismatch population, the 
guidelines suggest using a DCB over a stent, since the residual DS was ≤ 30%. If the 
guidelines are followed, only severe dissections (type C dissection) should be treated with a 
stent, whilst the rest of them could receive DCB treatment (6.0% of DS ≤ 30%) [1]. It is well 
known that in patients with functionally significant stenoses, FFR-guided PCI decreases the 
need of urgent revascularization compared with medical therapy alone [13]. Thus, these 
reverse mismatch lesions pose a higher clinical risk of future events and it is appropriate for 
them to be treated with stent implantation. 
In the left anterior descending artery (LAD) the majority of lesions with severe 
dissection had an FFR after BA of ≥ 0.75 which was independent of the severity of the 
dissection (Fig. 1B). Of note, all severe dissections in non-LAD lesions had an FFR after BA 
≥ 0.75 (Fig. 1C, D). The dissection type after BA does not correlate with residual FFR as 
seen in Figure 2. Thus, FFR after BA measurements in LAD lesions could be recommended 
not just to reduce the number of stents in mismatch lesions, but also to prevent future adverse 
clinical events in reverse mismatch lesions, while lesions in the circumflex and right coronary 
artery could be safely treated with angiography alone. FFR-guided DCB treatment has 
several advantages compared to angiography-guided DCB application. A recent 
recommendation from an Asia-Pacific consensus group reported both angiographic and 
functional criteria for large de novo coronary lesions [9].  
The provisional strategy guided by physiology for de novo lesions are summarized in 
Figure 3. The first step for successful DCB treatment is to achieve optimal lesion preparation 
by pre-dilation balloon (non-compliant or scoring/cutting balloons) or a non-balloon device 
like atherectomy or rotablator. A balloon to artery ratio of 0.8 to 1.0 and an inflation pressure 
higher than nominal should be used. Thrombus aspiration for patients with STEMI should be 
performed in appropriate situations. The acceptable angiographic and functional criteria after 
BA to perform DCB treatment are TIMI grade 3 flow and FFR ≥ 0.75. In this FFR-guided 
DCB strategy, if the FFR after BA is ≥ 0.75, DCB treatment can be performed safely [3, 12]. 
The provisional DCB treatment guided by physiology aims to provide safer DCB treatment 
based on physiology according to all anatomical changes like dissection presence or severity, 
and residual stenosis occurring after BA. In a previous study comparing angiography to FFR-
guided DCB treatment for 167 lesions, there was a mismatch in 68.7% (57 of 83) of the 
population and a reverse mismatch in 7.1% (6 of 84) [1]. If an angiography-guided strategy 
was used, 57.5% (96 of 167) would need treatment with a DES, whilst using an FFR-guided 
strategy only 19.2% (32 of 167) need a DES; this 66.7% reduction in stent usage occurred 
without increasing safety concerns. Lesions in the reverse mismatch population pose a higher 
clinical risk of future events however whilst the angio-guided approach recommends treating 
with a DCB since the residual DS is < 30%, the FFR-guided approach recommends treating 
with a DES since the residual FFR is < 0.75 and hence, it could prevent possible future 
events.  
Recently, it was demonstrated that instantaneous wave-free ratio (iFR), an alternative 
measure that does not require the administration of adenosine, measured right after BA is safe 
and effective for de novo coronary lesions [26]. The cutoff value of iFR right after BA used 
to define functionally nonsignificant residual stenotic lesions was 0.86 that iFR-guided PCB 
treatment is safe and effective for de novo major epicardial coronary lesions with good 
anatomical patency at 9-month follow-up and showed good long-term clinical outcomes in 
patients with iFR ≥ 0.86 after BA. As alternative methods to FFR or iFR, functional coronary 
imaging, quantitative flow ratio, have recently emerged, allowing wire-free functional 
assessment of stenosis severity based on a computational fluid dynamics model or 
mathematical assumptions of coronary flow. Although previous studies have demonstrated 
excellent correlations and diagnostic agreements with FFR [27, 28], an evaluation of the 
diagnostic performance and agreement of QFR using FFR or iFR as reference standards in 
the situation of BA is needed. 
 
Medical treatment 
Easy to heal and the lower risk of target lesion thrombosis in lesions treated with a DCB 
makes prolonged DAPT therapy unnecessary. The European Society of Cardiology guideline 
recommends 6 months of DAPT treatment, however, shorter durations of 1–3 months after 
DCB have not been associated with any increased risk of long-term adverse outcomes 
compared with BMS or DES [7]. Looking at the previous data, when 1st generation DES was 
used, stent thrombosis occurred 0.6% per year [29], and 2nd generation stent occurred 0.3% of 
stent thrombosis per year [30]. In the BASKET-SMALL 2 study for small de no lesions (n = 
758 patients), DCB was non-inferior to DES for major adverse cardiovascular events (cardiac 
death, non-fatal MI, and target vessel revascularization) for up to 12 months (7.5% vs. 7.3%; 
hazard ratio 0.97 [95% CI 0.58–1.64], p = 0.918) [31]. The thrombosis rate (probable or 
definite) in DCB treated lesions was numerically lower than DES (0.8% vs. 1.1%; HR 0.73 
[0.16–3.26]) despite DAPT being continued for only 1 month in the DCB arm and 6–12 
months in the DES arm. Major bleeding in DCB arm was also numerically lower than the 
DES arm (1.1% vs. 2.4%; HR 0.45 [0.14–1.46]). 
High-intensity statin therapy may provide incremental clinical benefits after DCB 
application. It is well known that statin treatment causes plaque regression and improves 
clinical outcomes when used for either primary or secondary prevention. BA creates 
iatrogenic plaque dissection and causes plaque redistribution, and DCB provides local drug 
delivery to prevent restenosis. After DCB treatment, cholesterol-lowering drugs may cause 
greater plaque regression compared to statin only treatment without PCI. Regarding the 
effects of statin therapy, a previous study demonstrated that a clear reduction of lipid core 
was only observed in thin-cap fibroatheromas, suggesting that changes in plaque composition 
following statin therapy might occur earlier and to a greater degree in vulnerable plaque 
compared to stable plaque [32]. Another study showed that DCB treatment with high dose 
statins caused persistent patency with plaque redistribution without chronic elastic recoil and 
restored coronary blood flow resulting in increased lumen areas at follow-up [33]. These 
results suggest that there will be regression of plaque after DCB treatment through high dose 
statin therapy. Therefore, high intensity statin therapy can reinforce the efficacy of DCB 
treatment. 
 
Conclusions 
For successful DCB treatment, optimal lesion preparation using optimally sized scoring 
balloons is essential. Ideal lesion preparation should be assessed by measuring flow status 
using physiological indexes such as FFR rather than by estimating stenotic severity from 
angiography alone. Although not all coronary lesions require FFR measurement, if the lesion 
subtends a large amount of myocardium such as lesions in the proximal LAD, they should be 
assessed with FFR. The physiology-guided provisional strategy suggests that DCB treatment 
should only be performed if adequate coronary flow is obtained after optimal balloon 
angioplasty, with newer generation DES used in cases of inadequate flow. For successful 
DCB treatment, there is a need for better technology that can make plaque modifications safe 
and effective. In addition, the importance of medical treatment to maximize the effect of 
DCB (anti-thrombotics and cholesterol-lowering drugs) cannot be overemphasized. 
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Figure 1. Correlation between fractional flow reserve (FFR) after balloon angioplasty (BA) 
and residual diameter stenosis; A. Overall population; B. Left anterior descending artery; C. 
Left circumflex artery; D. Right coronary artery. Reused with permission from: Int J 
Cardiovasc Imaging 2019; 35: 1945–1954; DS — diameter stenosis. 
 
Figure 2. Fractional flow reserve (FFR) after balloon angioplasty (BA) according to 
dissection type; A. Distribution of FFR; B. Proportion of high and low FFR groups. Modified 
with permission from: Int J Cardiovasc Imaging 2019; 35: 1945–1954.  
 
Figure 3. Provisional drug-coated balloon (DCB) strategy guided by fractional flow reserve 
(FFR). The acceptable angiographic and functional criteria after balloon angioplasty (BA) to 
perform DCB treatment are Thrombolysis In Myocardial Infarction (TIMI) 3 grade flow and 
FFR ≥ 0.75; DES — drug-eluting stent. 
 
Figure 4. Representative cases for provisional drug-coated balloon strategy guided by 
fractional flow reserve. 
 




